Obesity-Related Chronic Kidney Disease: From Diagnosis to Treatment

Overview

Journal Diagnostics (Basel)

Date 2025 Jan 25

PMID 39857056

Authors

Elena Avgoustou

Ilektra Tzivaki

Garyfalia Diamantopoulou

Tatiana Zachariadou

Despoina Avramidou

Vasileios Dalopoulos

Alexandros Skourtis

Affiliations

Soon will be listed here.

Abstract

Obesity has emerged as a global epidemic with far-reaching health complications, including its role as an independent risk factor for chronic kidney disease (CKD). Increasing evidence suggests that obesity contributes to CKD through multiple mechanisms, including chronic inflammation, hemodynamic alterations, insulin resistance, and lipid accumulation. These processes can culminate in histopathological changes collectively referred to as obesity-related glomerulopathy (ORG). This review aims to provide a comprehensive overview of the current knowledge regarding the prevalence, clinical manifestations, and pathophysiology of ORG. Furthermore, we emphasize the importance of identifying key biomarkers that facilitate the early detection of ORG. Finally, we explore emerging therapeutic strategies that offer promise in mitigating this growing global health crisis.

Citing Articles

Beneficial Effects of Butyrate on Kidney Disease.

Diep T, Liu H, Yan L Nutrients. 2025; 17(5).

PMID: 40077642 PMC: 11901450. DOI: 10.3390/nu17050772.

References

Mullins T, Schock-Kusch D, Gallo L . Transdermal Measurement of Glomerular Filtration Rate in Preclinical Research. Methods Mol Biol. 2023; 2664:309-315. DOI: 10.1007/978-1-0716-3179-9_19. View

Lemoine S, Guebre-Egziabher F, Sens F, Nguyen-Tu M, Juillard L, Dubourg L . Accuracy of GFR estimation in obese patients. Clin J Am Soc Nephrol. 2014; 9(4):720-7. PMC: 3974350. DOI: 10.2215/CJN.03610413. View

Bakris G, Agarwal R, Chan J, Cooper M, Gansevoort R, Haller H . Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015; 314(9):884-94. DOI: 10.1001/jama.2015.10081. View

Dalle Grave R . The Benefit of Healthy Lifestyle in the Era of New Medications to Treat Obesity. Diabetes Metab Syndr Obes. 2024; 17:227-230. PMC: 10798050. DOI: 10.2147/DMSO.S447582. View

Connor K, Denby L . MicroRNAs as non-invasive biomarkers of renal disease. Nephrol Dial Transplant. 2019; 36(3):428-429. PMC: 7898020. DOI: 10.1093/ndt/gfz183. View

Popoviciu M, Paduraru L, Yahya G, Metwally K, Cavalu S . Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. Int J Mol Sci. 2023; 24(13). PMC: 10341852. DOI: 10.3390/ijms241310449. View

Wei L, Li Y, Yu Y, Xu M, Chen H, Li L . Obesity-Related Glomerulopathy: From Mechanism to Therapeutic Target. Diabetes Metab Syndr Obes. 2021; 14:4371-4380. PMC: 8560069. DOI: 10.2147/DMSO.S334199. View

Frias J, Davies M, Rosenstock J, Perez Manghi F, Lando L, Bergman B . Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021; 385(6):503-515. DOI: 10.1056/NEJMoa2107519. View

Wang M, Wang Z, Chen Y, Dong Y . Kidney Damage Caused by Obesity and Its Feasible Treatment Drugs. Int J Mol Sci. 2022; 23(2). PMC: 8775419. DOI: 10.3390/ijms23020747. View

10.

Wang G, Kwan B, Lai F, Choi P, Chow K, Li P . Intrarenal expression of microRNAs in patients with IgA nephropathy. Lab Invest. 2009; 90(1):98-103. DOI: 10.1038/labinvest.2009.118. View

11.

Nawaz S, Chinnadurai R, Al-Chalabi S, Evans P, Kalra P, Syed A . Obesity and chronic kidney disease: A current review. Obes Sci Pract. 2023; 9(2):61-74. PMC: 10073820. DOI: 10.1002/osp4.629. View

12.

Hsu W, Hsiao P, Lin P, Chen S, Lee M, Shin S . Effect of metformin on kidney function in patients with type 2 diabetes mellitus and moderate chronic kidney disease. Oncotarget. 2018; 9(4):5416-5423. PMC: 5797060. DOI: 10.18632/oncotarget.23387. View

13.

Hung S, Chang Y, Liu J, Kuo K, Chen Y, Hsu C . Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. Lancet Diabetes Endocrinol. 2015; 3(8):605-14. DOI: 10.1016/S2213-8587(15)00123-0. View

14.

Bjornstad P, Pyle L, Cherney D, Johnson R, Sippl R, Wong R . Plasma biomarkers improve prediction of diabetic kidney disease in adults with type 1 diabetes over a 12-year follow-up: CACTI study. Nephrol Dial Transplant. 2017; 33(7):1189-1196. PMC: 6030887. DOI: 10.1093/ndt/gfx255. View

15.

Bruci A, Tuccinardi D, Tozzi R, Balena A, Santucci S, Frontani R . Very Low-Calorie Ketogenic Diet: A Safe and Effective Tool for Weight Loss in Patients With Obesity and Mild Kidney Failure. Nutrients. 2020; 12(2). PMC: 7071259. DOI: 10.3390/nu12020333. View

16.

Serino G, Pesce F, Sallustio F, De Palma G, Cox S, Curci C . In a retrospective international study, circulating miR-148b and let-7b were found to be serum markers for detecting primary IgA nephropathy. Kidney Int. 2015; 89(3):683-92. DOI: 10.1038/ki.2015.333. View

17.

Yu J, Yu C, Feng B, Zhan X, Luo N, Yu X . Intrarenal microRNA signature related to the fibrosis process in chronic kidney disease: identification and functional validation of key miRNAs. BMC Nephrol. 2019; 20(1):336. PMC: 6712721. DOI: 10.1186/s12882-019-1512-x. View

18.

Veenboer P, Hobbelink M, Bosch J, Dik P, van Asbeck F, Beek F . Diagnostic accuracy of Tc-99m DMSA scintigraphy and renal ultrasonography for detecting renal scarring and relative function in patients with spinal dysraphism. Neurourol Urodyn. 2014; 34(6):513-8. DOI: 10.1002/nau.22608. View

19.

Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M . Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006; 17(7):2034-47. DOI: 10.1681/ASN.2005101085. View

20.

Kovesdy C . Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022; 12(1):7-11. PMC: 9073222. DOI: 10.1016/j.kisu.2021.11.003. View